Q2 2025 Ascelia Pharma AB Earnings Call Transcript
Key Points
- Ascelia Pharma AB (FRA:7ZA) is nearing the submission of its New Drug Application (NDA) for Orviglance, a first-in-class diagnostic drug for liver cancer imaging, which addresses a significant unmet need.
- Orviglance has received orphan drug designation from the FDA, targeting a global market opportunity of USD800 million annually.
- The company has completed all clinical development for Orviglance, including a successful global Phase 3 study, demonstrating strong efficacy and safety results.
- Ascelia Pharma AB (FRA:7ZA) has secured SEK43 million from the exercise of warrants, strengthening its financial position.
- The company is actively pursuing partnerships for the commercialization of Orviglance, which could leverage existing market capabilities and optimize revenue potential.
- The NDA submission for Orviglance has been delayed from the first half of August to early September, indicating potential timeline risks.
- There are concerns about the lack of specificity as an endpoint in the Phase 3 study, which could impact the evaluation of long-term clinical benefits.
- The company faces significant competition from existing gadolinium-based contrast agents, despite their associated safety concerns.
- Ascelia Pharma AB (FRA:7ZA) has a limited cash runway, reaching only until the end of the year, which may necessitate additional financing if partnering or FDA approval is delayed.
- The company has not yet secured a commercialization partner, which is crucial for the successful market launch of Orviglance.
Good morning, and welcome to today's events, which will focus on the half-year financial result from a Ascelia Pharma. Representing a Ascelia Pharma, we are joined by Deputy CEO and CFO Julie Waras Brogren.
This event will be recorded and following editing, shared on our platform and on a Ascelia's platform as well. All investors are more than welcome to submit questions during the events, and I will pass them to (inaudible) and then it will either during the presentation or after the presentation, answer the questions.
So with that said, I hope we get a really good event and (inaudible), well, welcome (inaudible) and the microphone is yours.
Thank you, Claus. It's good to be here. I'm looking forward to the discussion. I know you have some good questions as well, so, let's start going through our -- you can see our activities and results for this last quarter and a half year. The focus is on NDA approaching for the -- for [over
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
